Prognostic Modeling in Early Stage Lung Cancer: An Evolving Process from Histopathology to Genomics

Thoracic Surgery Clinics

Volumn 17, Issue 2, 2007, Pages 167-173

  Harpole Jr , David H ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CISPLATIN; DOCETAXEL; GEMCITABINE; NAVELBINE;

CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER SCREENING; CANCER SURGERY; CANCER THERAPY; CLINICAL TRIAL; DISEASE SEVERITY; EXTERNAL VALIDITY; GENOMICS; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; INTERNAL VALIDITY; LUNG CANCER; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVIEW;

CARCINOMA, NON-SMALL-CELL LUNG; GENOMICS; HUMANS; LUNG NEOPLASMS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS; TUMOR MARKERS, BIOLOGICAL;

EID: 34249861387     PISSN: 15474127     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thorsurg.2007.03.014     Document Type: Review

References (27)

1. Parker S.L., Tong T., Bolden S., et al. Cancer statistics. CA Cancer J Clin 47 1 (1997) 5-27
2. Naruke T., Goya T., Tsuchiya R., et al. Prognosis and survival in resected lung carcinoma based on the international staging system. J Thorac Cardiovasc Surg 96 (1988) 440-447
3. Strauss G.M., Kwiatkowski D.J., Harpole Jr. D.H., et al. Molecular and pathologic analysis of stage I non-small cell lung carcinoma of the lung. J Clin Oncol 13 (1995) 1265-1279
4. Harpole D.H., Herndon J.E., Young W.G., et al. Stage I non-small cell lung cancer: a multivariate analysis of treatment and patterns of recurrence. Cancer 76 (1995) 787-796
5. Kato H., Ichinose Y., Ohta M., et al., Japan Lung Cancer Research Group on Postsurgical Adjuvant Chemotherapy. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med 350 17 (2004) 1713-1721
6. Arriagada R., Bergman B., Dunant A., et al., International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 350 4 (2004) 351-360
7. Douillard J., Rosell R., Delena M., et al. ANITA: phase III adjuvant vinorelbine (N) and cisplatin (P) versus observation (OBS) in completely resected (stage I-III) non-small cell lung cancer (NSCLC) patients (pts): final results after 70-month median follow-up. Proceedings of the American Society of Clinical Oncology (2005) Abstract No: 7013
8. Winton T., Livingston R., Johnson D., et al. Vinorelbine plus cisplatin vs. observation in resected non-small cell lung cancer. N Engl J Med 352 25 (2005) 2589-2597
9. Strauss G.M., Herndon J.E., Maddaus M.A., et al. Adjuvant chemotherapy in stage IB non-small cell lung cancer (NSCLC): update of Cancer and Leukemia Group B (CALGB) protocol 9633. Proceedings of the American Society of Clinical Oncology (2006) Abstract No. 7007
10. Harpole Jr. D.H., Herndon J.E., Wolfe W.G., et al. A prognostic model of recurrence and death in stage I non-small cell lung cancer utilizing presentation, histopathology, and oncoprotein expression. Cancer Res 55 (1995) 51-56
11. Harpole Jr. D.H., Marks J.R., Richards W., et al. Localized adenocarcinoma of the lung: oncogene expression of erbB-2 and p53 in 150 patients. Clin Cancer Res 1 (1995) 659-664
12. Harpole Jr. D.H., Richards W.G., Herdon J.E., et al. Angiogenesis and molecular biologic sub-staging in patients with stage I non-small cell lung cancer. Ann Thorac Surg 61 (1996) 1470-1476
13. Kwiatkowski D.J., Harpole Jr. D.H., Godleski J., et al. Molecular pathologic substaging in 244 STAGE I non-small cell lung cancer patients: clinical implications. J Clin Oncol 16 (1998) 2468-2477
14. D'Amico T.A., Massey M., Herndon II J.E., et al. A biologic risk model for stage I lung cancer: immunohistochemical analysis of 408 patients using 10 molecular markers. J Thorac Cardiovasc Surg 117 (1999) 736-743
15. D'Amico T.A., Alioa T.A., Herndon J.E., et al. Molecular biologic sub-staging in patients with stage I non-small cell lung cancer: risk stratification according to sex and histological subtype. Ann Thorac Surg 69 (2000) 882-886
16. D'Amico T.A., Moore M.B., Aloia T.A., et al. Predicting the site of metastases from lung cancer using molecular biologic markers. Ann Thorac Surg 72 (2001) 1144-1148
17. West M., Blanchette C., Dressman H., et al. Predicting the clinical status of human breast cancer by using gene expression profiles. Proc Natl Acad Sci USA 98 20 (2001) 11462-11467
18. Pittman J., Huang E., Dressman H., et al. Models for individualized prediction of disease outcomes based on multiple gene expression patterns and clinical data. Proc Natl Acad Sci USA 101 (2004) 8431-8436
19. Pittman J., Huang E., Wang Q., et al. Bayesian analysis of binary prediction tree models for retrospectively sampled outcomes. Biostatistics 5 (2004) 587-601
20. Nevins J.R., Huang E.S., Dressman H., et al. Towards integrated clinic-genomic models for personalized medicine: combining gene expression signatures and clinical factors in breast cancer outcomes prediction. Hum Mol Genet 12 (2003) R153-R157
21. Garber M.E., Troyanskaya O.G., Schluens K., et al. Diversity of gene expression in adenocarcinoma of the lung. Proc Natl Acad Sci USA 98 24 (2001) 13784-13789
22. Bhattacharjee A., Richards W.G., Staunton J., et al. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci USA 98 24 (2001) 13790-13795
23. Beer D.G., Kardia S.L., Huang C.C., et al. Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med 8 8 (2002) 816-824
24. Wigle D.A., Jurisica I., Radulovich N., et al. Molecular profiling of non-small cell lung cancer and correlation with disease-free survival. Cancer Res 62 11 (2002) 3005-3008
25. Kikuchi T., Daigo Y., Katagiri T., et al. Expression profiles of non-small cell lung cancers on cDNA microarrays: identification of genes for prediction of lymph-node metastasis and sensitivity to anti-cancer drugs. Oncogene 22 14 (2003) 2192-2205
26. Raponi M., Zhang Y., Yu J., et al. Gene expression signatures for predicting prognosis of squamous cell and adenocarcinomas of the lung. Cancer Res 66 15 (2006) 7466-7472
27. Potti A., Mukherjee S., Prince R., et al. A genomic strategy to refine prognosis and therapeutic decision for adjuvant therapy in non-small cell lung carcinoma. N Engl J Med 355 6 (2006) 570-580